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ABSTRACT
Objective We aimed to find out if trialists involve patients 
and the public in numerical aspects of trials, how and what 
are the barriers and facilitators to doing it.
Design We developed a survey based on the Theoretical 
Domains Framework. We used a mixed methods approach 
to analyse the data and to identify important domains.
Setting Online survey targeting UK- based trial units.
Participants Stakeholders working in UK- based clinical 
trials, 18 years old or over, understand English and agree 
to take part in the study.
Outcome measures Trialists’ behaviour of involving 
patients and the public in numerical aspects of trials and 
its determinants.
Results We included 187 respondents. Majority were 
female (70%), trial managers (67%) and involved public 
and patient partners in numerical aspects of trials (60%). 
We found lack of knowledge, trialists’ perception of public 
and patient partners’ skills, capabilities and motivations, 
scarce resources, lack of reinforcement, and lack of 
guidance were barriers to involving public and patient 
partners in numerical aspects of trials. Positive beliefs 
about consequences were an incentive to doing it.
Conclusions More training, guidance and funding 
can help trialists involve patient and public partners in 
numerical aspects, although they were uncertain about 
public and patient partners’ motivation to be involved. 
Future research should focus on identifying public and 
patient partners’ motivations and develop strategies to 
improve the communication of numerical aspects.
BACKGROUND
Patient and public involvement (PPI) has 
been defined as ‘research being carried 
out ‘with’ or ‘by’ members of the public 
(including patients and carers) rather than 
‘to’, ‘about’ or ‘for’ them’ (http://www. invo. 
org. uk/). PPI activity has become increas-
ingly common in trials in the UK for several 
reasons: its supporters believe it makes 
research more relevant and it is, morally, the 
right thing to do. It is also a requirement 
from major funders, including the National 
Institute for Health Research.1
In a trial context, patient and public part-
ners have been primarily involved in agenda 
setting, steering committees, ethical review, 
protocol development and piloting,2 but 
PPI remains seen as tokenistic and a ticking 
box exercise in many settings.3 4 Trials are 
primarily quantitative research and often 
key decisions are based on numerical aspects 
and their discussion. However, the extent to 
which patients and the public get involved 
in those discussions is unknown, with some 
evidence suggesting communication of statis-
tical aspects of trials needs to be clearer in 
order to achieve meaningful involvement.5 
At the same time, involving patients and the 
public in the statistical and health economics 
aspects of trials can result in enriching data 
interpretation and better research, with more 
robust and implementable evidence.6 7
PPI can be considered a professional 
behaviour since it involves a series of actions 
Strengths and limitations of this study
 ► This is the first investigation of trialists’ practice re-
garding involving patients and the public in numeri-
cal aspects of trials and aimed at UK- based trialists.
 ► We achieved a wide representation of trialists work-
ing in clinical trials in the UK.
 ► We described current practice as well as determi-
nants of behaviour using a theory- informed approach 
based on the Theoretical Domains Framework.
 ► Respondents’ interpretation of involving patients 
and the public in numerical aspects varied, so the 
results apply to a spectrum of behaviours.
 ► Respondents are likely to have stronger views of 
patient and public involvement (PPI) and PPI in nu-
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to accomplish a goal (such as inviting a patient partner 
to contribute to a discussion). To understand a specific 
behaviour and its determinants, it can be helpful to use 
behavioural theory to provide a systematic and repli-
cable framework. The Theoretical Domains Framework 
(TDF) was developed to focus on healthcare professional 
behaviour, specifically around evidence- based medi-
cine and the adoption of new practices, and is made of 
up of 15 behavioural domains.8 Previous work has used 
the TDF to explore researchers’ beliefs related to PPI in 
health research,3 but to our knowledge this is the first 
application of the framework to explore PPI in trials, and 
in particular PPI in numerical aspects of trials. We aimed 
to use a theory- informed approach to find out whether 
trialists involve patient and public partners in numerical 




The survey was divided into the following sections:
 ► Demographic questions.
 ► Definition of numerical aspects of trials.
 ► General questions about PPI in numerical aspects of 
trials.
 ► TDF questions.
Demographic questions focused on characterising our 
sample (age, gender, trial work experience and role). 
We agreed on the definition of ‘numerical aspects of 
trials’ (‘any aspects of a trial where people measure (or 
plan to measure), manage, analyse or share information 
that is presented as one or more numbers’) through an 
iterative process involving 13 members of the Health 
Services Research Unit at the University of Aberdeen 
(including a variety of different roles in the unit, such as 
a professor of health services research, a health econo-
mist, a statistician, trial manager, PPI/engagement coor-
dinator, research fellow, assistant researcher and quality 
assurance manager). The definition was included in the 
survey. Respondents were asked about their current prac-
tice regarding involving public and patient partners in 
numerical aspects of trials.
The TDF was developed as a theoretical framework 
and includes behavioural theories and constructs and 
proposes that determinants of professionals’ behaviour 
can be clustered in ‘domains’. The TDF, after an update 
from Presseau et al,9 consists of 15 domains. The TDF 
section of our survey was developed based on previous 
surveys10 11 and was reviewed by the project team and by 
an expert in TDF research (ED).
The survey was piloted by eight staff or student 
members from the University of Aberdeen. The survey 
was administered and delivered through SurveyMonkey. 
Informed consent was requested and embedded in 
the survey. The final version contained 43 questions 
consisting of both closed and open questions (see 
online supplemental appendix 1 – questionnaire). The 
participants were able to withdraw from the survey at 
any time.
Target population
The target population was any stakeholder working in 
clinical trials (from here onwards called a ‘trialist’), for 
example trial managers, principal or chief investigators, 
statisticians, clinicians, patient or public partners, PPI 
coordinators, and research fellows. To take part in our 
study, participants needed to be 18 years old or over, work 
in a UK clinical trial’s unit, understand English and agree 
to take part in the study.
Participant recruitment
The questionnaire was disseminated using an online 
link via email and social media. We used a snowball 
approach to recruit survey respondents by dissemi-
nating the survey to colleagues, known networks and 
through social media (LinkedIn, Twitter, Facebook and 
Instagram). We used common hashtags (#) and pictures 
to encourage responses. We contacted stakeholders 
via professional mailing lists to ask to disseminate our 
survey, such as a PPI coordinator’s mailing lists, clinical 
trial unit websites and the UK Clinical Research Collab-
oration. The survey link was active from 11 June 2019 
to 1 July 2019.
Survey analysis
The survey analysis was divided into two parts: analysis of 
closed- ended questions (as quantitative data) and analysis 
of open questions (as qualitative data). We exported the 
data into Stata V.15 and generated statistical summaries 
of the closed- ended questions. The Likert scale questions 
used a scale from 1 (weaker agreement/confidence/etc) 
to 7 (stronger agreement/confidence/etc). They are 
presented using median, IQR and counts. Binary ques-
tions (with only two possible answers; eg, yes/no) are 
presented as n (%) out of the available answers. We split 
the results into respondents who self- reported to perform 
the behaviour assessed (involving public and patient part-
ners in numerical aspects of trials) and those who did not 
or were not sure. When questions included a category 
named ‘other’, the answers given were grouped together, 
coded and counted. Analysis of open- ended questions 
was done using a deductive thematic analysis approach 
informed by the TDF by one author (BG). If data did 
not fit into the prespecified TDF domains, an inductive 
approach was taken. We compared the quantitative and 
qualitative data to identify the most salient domains of the 
TDF that explained the behaviour. This process was done 
by one author (BG) and reviewed using a subset of qual-
itative data by a second author (KG). We did not under-
take any statistical testing since our aim was to describe 
the data and not to test hypotheses. We used Stata V.15 for 
the purposes of summarising quantitative data and Micro-
soft Word to analyse qualitative data.
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Identifying the most ‘relevant’ domains to involve patients and 
the public in numerical aspects of trials
In order to establish the barriers and facilitators of the 
target behaviour (PPI in numerical aspects of trials), 
criteria were developed to determine which domains 
of the TDF were ‘relevant’ for this behaviour based on 
previous TDF research.12 Relevant domains were those 
that were considered to show variation in reported 
behaviour/beliefs between trialists who involve patients 
and the public in numerical aspects and those who do 
not.
PPI in the study
Our study is part of a larger project, the Patient and 
public Involvement in Numerical aspects of Trials 
(PoINT) project (https://www. abdn. ac. uk/ hsru/ 
what-  we- do/ research/ projects/ point-  827. php), 
where PPI has been sought at all stages including in 
its design and via focus groups. The current survey 
was piloted by three public members.
RESULTS
A total of 317 people accessed the survey. From these 
317, we excluded from the final analysis 130 people for 
the following reasons: 31 did not provide any informa-
tion and 99 did not respond to any TDF- focused ques-
tions. Therefore, the 187 participants who replied 
to at least one TDF question were included in the 
final analysis (figure 1). Online supplemental table 
1 provides the demographic information based on 
respondent status. Respondents and non- respondents 
had similar features with a few exceptions: there was 
a higher percentage of women in the group of non- 
respondents compared with respondents (n=82, 83% 
vs n=130, 70%), and there was a higher percentage 
of respondents involved in all stages of trials (n=75, 
40%) compared with non- respondents (n=25, 25%). 
However, the most common trial stages that respon-
dents and non- respondents were involved in were the 
same: trial design (around 50%) and undertaking the 
trial (around 50%). There was a higher proportion 
of statisticians in the respondents group (n=29, 16%) 
compared with non- respondents (n=8, 8%). A larger 
percentage of respondents reported to involve patient 
and public partners in numerical aspects of trials daily 
compared with non- respondents (n=48, 26% vs n=11, 
11%).
Characteristics of respondents
Table 1 shows the characteristics of the respondents. 
Of the respondents, 70% were women (n=130). 
Respondents were based across the UK, with the 
highest percentage coming from London (n=33, 
18%). Around 40% were involved in all stages of the 
trial (n=75) and about half were involved in design, 
conduct and dissemination. One- third were involved 
in the analysis of the trial. Most respondents were 
trial managers (n=125, 67%); eight respondents (4%) 
were patient partners in trials. About 37% (n=69) had 
been working in trials for more than 10 years and 31% 
for less than 5 (n=57).
Respondents’ current practice of involving public and patient 
partners in numerical aspects of trials
Around 62% of respondents said they involve public 
and patient partners in numerical aspects of trials 
(n=116); 26% said they did not (n=48) and 12% said 
they were not sure (n=23). From the trialists involving 
public and patient partners in numerical aspects of 
trials, 24% have been working in the field for less 
than 5 years (n=28) vs 41% who did not involve public 
and patient partners in numerical aspects of trials 
(n=29). Some respondents were uncertain about 
what involving public and patient partners in numer-
ical aspects meant, with definitions ranging from any 
discussion about numbers to involvement in the statis-
tical analysis.
The most common stages of trials to involve public 
and patient partners in numerical aspects were trial 
design (n=86, 74%) and dissemination (n=84, 72%). 
About half involved public and patient partners in 
the analysis and interpretation. Respondents exem-
plified how they involved public and patient partners 
in numerical aspects: in management and steering 
committees where numerical data are discussed; 
sample size calculations, and specifically discussing 
effect sizes, clinically important differences and non- 
inferiority margins; dissemination of results and 
aiding to increase clarity of communication with trial 
participants; grant applications and trial design stage; 
when and how to collect data; and defining outcomes. 
Comments made about involving public and patient 
partners in the statistical analysis came from those 
Figure 1 Flow of participants. *Demographic information by 
respondent status is presented in online supplemental table 
1. TDF, Theoretical Domains Framework.
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who did not see an interest from public and patient 
partners in getting involved. For example:
I’ve also yet to have any PPI members say they would 
like to be more involved in this side of things; except 
for post- analysis when considering the qualitative and 
quantitative aspects together. (Trial manager and 
statistician, involves)
Domains influencing trialists in involving patients and the 
public in numerical aspects of trials
TDF domains selected as the most relevant for the target 
behaviour are presented in table 2; all TDF domain results 
are presented in online supplemental table 2. Table 3 
summarises the themes identified from the responses to 
open questions. By comparing the quantitative and qual-
itative data, we identified knowledge, skills, beliefs about 
capabilities, beliefs about consequences, reinforcement, 
environmental context and resources, social influences 
and behavioural regulation as being salient TDF domains. 
We identified an additional theme within the data on 
‘trial communication culture’ that did not fit within the 
TDF domains. Each of the salient TDF domains and the 
additional theme are presented.
Table 1 Descriptive statistics by trialists’ current practice 







Trialists who do 
not involve PPP in 
numerical aspects 
or do not know 
(n=71) Total
Age (years)
  18–24 1 (0.9) 1 (1.4) 2 (1.1)
  25–34 32 (27.6) 30 (42.3) 62 (33.2)
  35–44 38 (32.8) 12 (16.9) 50 (26.7)
  45–54 25 (21.6) 16 (22.5) 41 (21.9)
  55–64 14 (12.1) 8 (11.3) 22 (11.8)
  65+ 5 (4.3) 2 (2.8) 7 (3.7)
  Rather not say 1 (0.9) 2 (2.8) 3 (1.6)
Gender
  Female 80 (69.0) 50 (70.4) 130 (69.5)
  Male 33 (28.4) 17 (23.9) 50 (26.7)
  Other 2 (2.8) 2 (1.1)
  Prefer not to say 3 (2.6) 2 (2.8) 5 (2.7)
Work location
  England 9 (7.8) 8 (11.3) 17 (9.1)
  North East England 4 (3.4) 3 (4.2) 7 (3.7)
  North West England 7 (6.0) 7 (9.9) 14 (7.5)
  Yorkshire and the 
Humber
8 (6.9) 5 (7.0) 13 (7.0)
  West Midlands 10 (8.6) 2 (2.8) 12 (6.4)
  East Midlands 3 (2.6) 4 (5.6) 7 (3.7)
  South West England 9 (7.8) 2 (2.8) 11 (5.9)
  South East England 13 (11.2) 6 (8.5) 19 (10.2)
  London 19 (16.4) 14 (19.7) 33 (17.6)
  East England 3 (2.6) 1 (1.4) 4 (2.1)
  Northern Ireland 3 (2.6) 3 (4.2) 6 (3.2)
  Scotland 18 (15.5) 12 (16.9) 30 (16.0)
  Wales 10 (8.6) 4 (5.6) 14 (7.5)
Which aspects of the trial process are you directly involved in?
  Trial design 51 (44.0) 37 (52.1) 88 (47.1)
  Undertaking the trial 48 (41.4) 37 (52.1) 85 (45.5)
  Dissemination 55 (47.4) 34 (47.9) 89 (47.6)
  Analysis 36 (31.0) 23 (32.4) 59 (31.6)
  Overseeing 
committee
1 (0.9) 4 (5.6) 5 (2.7)
  All stages 56 (48.3) 19 (26.8) 75 (40.1)
Main role in trial
  Trial manager 81 (69.8) 44 (62.0) 125 (66.8)
  Chief investigator 2 (1.7) 1 (1.4) 3 (1.6)
  Statistician 16 (13.8) 13 (18.3) 29 (15.5)
  Health economist 2 (1.7) 1 (1.4) 3 (1.6)
  Qualitative 
researcher
6 (5.2) 2 (2.8) 8 (4.3)
  Patient partner 4 (3.4) 4 (5.6) 8 (4.3)







Trialists who do 
not involve PPP in 
numerical aspects 
or do not know 
(n=71) Total
  Researcher 6 (5.2) 1 (1.4) 7 (3.7)
  Systematic reviewer 1 (1.4) 1 (0.5)
  PPI lead 1 (0.9) 2 (2.8) 3 (1.6)
  Not reported 1 (0.9) 1 (0.5)
How long have you been working in trials?
  Less than 5 years 28 (24.1) 29 (40.8) 57 (30.5)
  Between 5 and 10 
years
44 (37.9) 17 (23.9) 61 (32.6)
  More than 10 years 44 (37.9) 25 (35.2) 69 (36.9)
When do you involve PPP in numerical aspects of trials?
  Never 2 (1.7) 2 (1.1)
  Rarely 10 (8.6) 10 (5.3)
  Regularly 72 (62.1) 72 (38.5)
  Every day 32 (27.6) 32 (17.1)
What stage of a trial do you involve PPP in the numerical aspects?
  Trial design 86 (74.1) 86 (46.0)
  Undertaking the trial 58 (50.0) 58 (31.0)
  Dissemination 84 (72.4) 84 (44.9)
  Undertaking the trial 58 (50.0) 58 (31.0)
  Overseeing 
committee
8 (6.9) 8 (4.3)
  No information 
available
2 (0.9) 4 (1.6)
Values are n (%).
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Knowledge: awareness of involving patients and the public in 
numerical aspects of trials
Respondents who involved public and patient partners in 
numerical aspects scored higher in the knowledge domain 
(median 4 vs 2 out of 7 (very familiar with PPI in numer-
ical aspects of trials) for those who did and did not involve 
public and patient partners in numerical aspects, respec-
tively). Knowledge was highlighted as a barrier to involving 
public and patient partners in numerical aspects of trials 
in the open questions where respondents discussed their 
lack of understanding of how or when to involve public 
and patient partners and suggesting training as a solution. 
Respondents highlighted public and patient partners’ lack 
of understanding of numerical aspects or trial processes as 
a barrier and suggested solutions to overcoming it, such as 
the use of visual aids or clear language.
Table 2 Responses to selected TDF questions by whether the respondent said they involved PPP in numerical aspects of 
trials – median (percentile 25 – percentile 75), count for scale variables or n (%) out of N for binary variables.
Respondents involve 
PPP (n=116)
Respondents do not 
involve PPP or are not 
sure (n=71)
TDF domain: knowledge
How familiar are you with involving PPP in numerical aspects of trials? 4 (3.0–5.0), 116 2 (1.0–3.0), 71
TDF domain: skills
Grade your own ability to involve PPP in numerical aspects of trials. 4 (3.0–5.0), 116 2 (1.0–4.0), 71
PPP skills
Do you think the PPP need to have particular experience or skills to be involved in numerical aspects of trials?
  Yes 52 (44.8) 41 (57.7)
  No 64 (55.2) 30 (42.3)
TDF domain: social/professional role
Is involving PPP in numerical aspects of trials an expected role within your job? 46 (39.7) 3 (4.2)
TDF domain: beliefs about capability
Do you feel confident in your ability to involve PPP in numerical aspects of trials? 4 (3.0–5.0), 111 3 (2.0–4.0), 62
Do you think that involving PPP in numerical aspects of trials is hard to deliver? 52 (44.8) 34 (47.9)
TDF domain: beliefs about consequences
There is a good balance between the challenges of involving PPP in numerical aspects of trials 
and the potential benefits.
68 (58.6) 22 (31.0)
TDF domain: reinforcement
You get recognition from PPP when you involve them in numerical aspects of trials. 35 (30.2) 12 (16.9)
You get recognition from work peers. 21 (18.1) 5 (7.0)
You get recognition from your manager. 23 (19.8) 6 (8.5)
TDF domain: environmental context and resources
Have the resources needed to involve PPP in numerical aspects of trials. 55 (47.4) 16 (22.5)
Employer provides support to involve PPP in numerical aspects of trials. 47 (40.5) 13 (18.3)
Employer provides training to involve PPP in numerical aspects of trials. 31 (26.7) 7 (9.9)
Involving PPP in numerical aspects of trials is compatible with daily practice. 63 (54.3) 17 (23.9)
PPPs are motivated to get involved in numerical aspects of trials. 59 (50.9) 14 (19.7)
TDF domain: social influences
Most people who are important think I should involve PPP in numerical aspects of trials. 5 (4.0–6.0), 94 3 (1.0–4.0), 50
Who encourages you to involve PPP in numerical aspects?
No encouragement. 7 (6.0) 14 (19.7)
Who is a barrier for you to involve PPP in numerical aspects?
No barrier. 47 (40.5) 13 (18.3)
TDF domain: behavioural regulation
Do you have a clear plan on…
Which numerical aspects of trials you should involve PPP with? 33 (28.4) 5 (7.0)
How you will involve PPP in numerical aspects of trials? 36 (31.0) 6 (8.5)
How often will you involve PPP in numerical aspects of trials? 37 (31.9) 4 (5.6)
Data shown as median (25th–75th percentile) and count for scale variables, or n (%) out of N for binary variables.
PPP, patient and public partner; TDF, Theoretical Domains Framework.
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Table 3 Open question responses coded by domain and grouped according to specific beliefs
Domains Specific belief Illustrating quotes
Knowledge Lack of clarity about 
what the task entails
“[What would help me involve PPP in numerical aspects of trials is…] Understanding what involving 
patients and public in numerical aspects of trials actually means, how it can be done and why it’s 
important.” (TM, NI)
”I think the main issue here is that there are very simple parts of numerical aspects of trials which we 
would always, and easily, involve PPI in: outcome measure acceptability and monitoring trial progress. I 
don’t know what other aspects might be, so I am imagining a training or knowledge failure on my part.” 
(TM, involves)
Training “[What would help me involve PPP in numerical aspects is…] training courses/workshops for members of 
the public on the numerical aspects of trials and also researchers on how to involve them.” (HE, NI)
“This is something that has never really been discussed at work. Nor have I seen any courses about doing 
this. More guidance is available about writing simply for patients but not specifically about numerical 
aspects. Some training would be welcome.” (TM, involves)
Knowledge of patient 
and public partners
“[What makes involving PPP in numerical aspects hard is…] Being confident patients have sufficient 
understanding to be able to contribute. Not sure what could make it easier, just need to be aware this may 
be a potential issue during initial discussions with focus group members for example.” (TM, involves)
“[What makes involving PPP in numerical aspects hard is…] a general lack of awareness of how trials 
(and research) work, which makes the initial engagement harder. It’s perfectly possible to overcome this 
though.” (Qualitative researcher, involves)
Skills Skills of patient and 
public partners
“…I would suggest that if you want to involve PPI in this [numerical] aspect then you would have to 
purposively approach PPI with a certain skill set or advertise for such PPI involvement.” (Coinvestigator, 
NI)
“It generally quite boring for the general public and they do need a basic level of numeracy and 
appreciation of research methods.” (Statistician, involves)
Social/professional 
role
Professional role “The grant applicants and senior team often take these decisions during trial design. I never had any 
impact on these decisions previously.” (Qualitative researcher, involves)
“Numerical roles already ‘assigned’ to statisticians and clinicians, so as Trial Manager, it can be difficult to 
enforce PPI involvement.” (TM, involves)
Beliefs about 
capability
Capabilities of patient 
and public partners
“Often numerical aspects are dictated by statistical programs and I think there is a general feeling that 
patient or public partners cannot grasp them.” (TM, NI)
“[A barrier to involve PPP in numerical aspects of trials is…] The PP themselves not being confident 
enough to comment.” (Coinvestigator, involves)
Beliefs about 
consequences
Impact on trial quality “Patients can help you work out how to disseminate the results for example, which graphs are easiest, 
which format of presenting an estimate (risk, number of days etc).” (Statistician, involves)
“Discussing numerical information to patients helps to distill complex findings into something more simple 
and acceptable. This helps the researcher to clearer think through what are the results, helps explain 
information clearly that improves the quality of the trial and will ultimately all benefit the patient.” (TM, 
involves)
Positive impact on 
patient and public 
partners
“The PPP can … increase their knowledge and understanding of their condition, new potential treatments, 
and the process involved in trials which evaluate treatments. This could reduce the information asymmetry 
between the patient and clinician in the future.” (HE, involves)
“Patients can understand the difficulties in running clinical research and trials. Showing recruitment figures 
and follow- up data is also beneficial as patients can see the results accumulating and the benefits of 
taking part in trials.” (TM, involves)
Negative impact on 
patient and public 
partners
”Makes participation stressful, unless the PP has pre- existing skills in stats or maths.” (Coinvestigator, 
involves)
Extra work/
responsibilities for the 
researcher
“It is more work for the researcher to involve patients/partners.” (Statistician, NI)
Uncertainty about 
impact on trial quality
“I think it could improve transparency of decision making through a trial process. I am less sure that will 
actually translate into ‘better’ decisions.” (CI, involves)
“I have answered no impact because I think it is unclear whether quality or the patient partner will get a 
positive impact. That is a question that needs investigation.” (CI, involves)
Reinforcement Lack of incentives “Having some tangible reward for your investment! It never does anything for your career, while other 
priorities do.” (Statistician, involves)
“It’s not really rewarded or recognised because it is an expected part of study design. All funders we work 




Funding “[What would help me involve PPP in numerical aspects is…] More funding for a PPI expert at our CTU. 
I am only funded 10% to be the coordinator for all PPI and to do a good job, I’d like to be able to spend 
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[What would remind me of doing PPI in numerical 
aspects of trials is…] A better understanding of what 
they can bring to other numerical aspects (other than 
oversight committees). (Trial manager, involves)
Visual aids (e.g. graphs) are useful. Someone on 
hand to answer questions and to help interpret the 
information provided. (Trial manager, involves)
Skills: ability or proficiency to involve patients and the public 
in numerical aspects of trials
Respondents who involved public and patient partners 
in numerical aspects scored higher in the skills domain 
(4 vs 3 out 7 (feeling able to involve public and patient 
partners in numerical aspects) for those who involve and 
those who do not, respectively). However, the answers to 
open questions relevant to the skills domain focused on 
patients and the public’s perceived lack of appropriate 
skills as a cause of concern and barrier to involve them in 
numerical aspects of trials.
[What makes involving public and patient partners in 
numerical aspects hard is public and patient partners…] 
Sufficient numeracy skills to understand simple ques-
tions around proportions etc. (Statistician, does not 
involve)
Half of the respondents believed public and patient part-
ners need to have a set of experiences or skills to be involved 
in numerical aspects of trials (44% (n=52) of trialists who 
involve public and patient partners in numerical aspects 
believed this vs 58% of those who do not (n=41)). When asked 
to specify what skills public and patient partners would need, 
some respondents focused on general skills such as lived 
experience of disease or communication. Other respondents 
thought public and patient partners had to have technical 
skills in order to be involved, such as numeracy or mathemat-
ical skills, statistical understanding, data interpretation and 
understanding of graphs, knowledge of trial methodology, 
trial processes and research in general.
Domains Specific belief Illustrating quotes
Time “I will need training to effectively include the public and the public will need training to effectively 
contribute to the research. This will take more time and resources that aren’t currently provided but if they 
were this would make it much easier.” (HE, NI)
Staff “[What would help me involve PPP in numerical aspects is…] More money, more trained help. The usual 
problems.” (TM, involves)
“[What would help me involve PPP in numerical aspects is…] Having a special person dedicated to 
running PPI work across trials.” (TM, involves)
Difficulty accessing 
willing volunteers
“It’s difficult to find public partners for any research, but when it’s something that’s specifically numerical I 
think that’s an even bigger challenge!” (Qualitative researcher and TM, involves)
“[What would help me involve PPP in numerical aspects is…] To know how or where to find participants 
that would be interested in participate.” (TM, NI)
Social influences Supportive team 
environment
“[What would help me involve PPP in numerical aspects is…] More of a group/team effort so that it is 
not just left to the trial manager to present to PPI members but the trial team as a whole takes on this 
responsibility.” (TM, involves)
“I think the enthusiasm of the chief investigator to include PPI members is important. If the investigator 
wants to involve PPI then it will happen but if the investigator is not bothered then it proves much more 
difficult to include someone.” (TM, involves)
Patient and public 
partners’ interest
“I would be happy to share details of the numerical analysis, but have never been asked to do so - they 
seem satisfied with the summary explanations provided.” (TM, NI)




Guidance “… If there was clear guidance and tools on how to do it and those tools could be easily integrated into 
management structures for running large scale studies then I would use them.” (CI, involves)
“[What would help me involve PPP in numerical aspects is…] Guidelines about PPI expectations for review 
of numerical aspects.” (TM, unsure about involvement)
Standard operating 
procedures
“[What would help me involve PPP in numerical aspects is…] have this implemented into SOPs [Standard 
Operating Procedures].” (TM, NI)
Trial communication 
culture
Lack of clarity in 
communication 
about numerical and 
statistical aspects of 
trials
“language and jargon used around sample size calculations etc in design discussions. Stats/
methodologists need to be open and able to discuss complex issues openly and simply.” (TM, involves)
“As a patient partner I feel very privileged… But as a retired maths teacher, I am very aware of the anxiety 
that numbers cause even otherwise very clever people - these anxieties will only be mitigated by more 
involvement at all levels, including the public.” (PPP, involves)
“If everyone in the research environment explained what the numbers mean clearly to all members of the 
team - that would make it easier to describe and facilitate involvement from patient or the public.” (TM, NI)
CI, chief investigator; CTU, clinical trial unit; HE, health economist; NI, does not involve PPP in numerical aspects; PPI, patient and public involvement; PPP, patient 
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Social or professional role: perception of own role and 
responsibilities in relation to involving patients and the public 
in numerical aspects of trials
Of respondents who involved public and patient partners in 
numerical aspects, 40% considered it an expected role within 
their jobs (n=46) vs 4% of those who did not involve public 
and patient partners (n=3). This was supported by qualitative 
data that showed that some trialists felt like other colleagues, 
including the chief investigator or statistician, would have to 
drive this process.
[A barrier to involving public and patient partners in 
numerical aspects of trials is…] It is not spoken about 
much and does not always relate directly to job roles. 
(Statistician, not sure about involvement)
Beliefs about capability: self-belief or confidence in the ability 
to involve patients and the public in numerical aspects of 
trials
Beliefs about trialists’ own capability did not seem to drive 
behaviour, with for example a similar percentage of respon-
dents who did (n=52, 45%) and who did not (n=34, 48%) 
involve public and patient partners finding the task difficult. 
However, responses to open questions highlighted trialists’ 
beliefs about public and patient partners’ capability as a 
barrier, suggesting public and patient partners feel intimi-
dated by numbers, do not grasp them or do not feel confi-
dent enough to comment.
[Two public and patient partners are involved in sample 
size considerations and recruitment figures…] Both are 
already confident with numbers/figures so only needed 
some support with specifics of presentation/meaning. 
(Trial manager, involves)
Beliefs about consequences: beliefs about outcomes of 
involving patients and the public in numerical aspects of trials
More than half of respondents who involved public and 
patient partners in numerical aspects believe there is a good 
balance between challenges and benefits of doing so (n=68), 
whereas only 30% shared that belief in those who did not 
involve (n=22). Responses to open questions showed sugges-
tions of positive consequences: focused on the project (such 
as improving the interpretation of the results, data collection 
tools and processes, dissemination, trial recruitment, under-
standing of missing data, interpretation of clinical signif-
icance) or the public and patient partners (leads to better 
understanding of the data and trial processes, more moti-
vated public and patient partners and better team commu-
nication). Some respondents suggested negative or no 
consequences, such as the impact on public and patient part-
ners being unclear or stressful, a disbelief that it can result in 
improved trial quality, and extra work and responsibilities for 
the researcher.
[Involving public and patient partners in numerical as-
pects of trials can have…] Multiple impacts, most impor-
tantly allowing trial teams to best understand how the 
key messages of a study can be translated directly to those 
patients living with condition under study. (Statistician, 
involves)
Reinforcement: whether there is external stimulus to involve 
patients and the public in numerical aspects of trials
A third of respondents believed there was recognition from 
public and patient partners when involving them in numer-
ical aspects of trials if they did so already (n=35) vs 17% of 
respondents who did not (n=12). Data from open questions 
supported these observations, with trialists mentioning a lack 
of tangible rewards or encouragement as barriers to involving 
public and patient partners in numerical aspects.
Environmental context and resources: factors related to the 
work setting that influence involving patients and the public 
in numerical aspects of trials
Less than half of trialists felt like they had the resources to 
support public and patient involvement in numerical aspects 
if they were doing it (n=55, 47%) and only 23% (n=16) if 
they were not. This was illustrated in several replies to the 
open questions, with respondents suggesting more resources 
(financial, human) could facilitate involvement, as well as 
support identifying interested public and patient partners.
Social influences: perception of how others see one’s role and 
how it impacts on the ability to involve patients and the public 
in numerical aspects of research
Of those who involve public and patient partners in numer-
ical aspects, 94% believe there is some type of encourage-
ment from others to do so (n=7) vs 80% of those who do 
not involve public and patient partners (n=14). Of those who 
involve public and patient partners, 40% believe that no one 
acted as a barrier to do the target behaviour (n=47) vs 18% of 
those who do not involve public and patient partners (n=13). 
Qualitative data showed support from colleagues as a team 
effort and encouragement from management or from public 
and patient partners were important factors in involving 
them in numerical aspects of trials.
Operationally, I don’t think PPI members really add a 
great deal. I also don’t think they tend to be interested 
in those [numerical] aspects. This may be because of the 
public perception of data and statistics as being hard/ob-
tuse/esoteric. (Trial manager and statistician, involves)
Behavioural regulation: perception of guidance or tools to 
manage or change PPI in numerical aspects of trials
About a third of those who involve public and patient 
partners in numerical aspects state they have a clear plan 
about which aspects to select, how and when, compared 
with around 7% of those who do not involve public 
and patient partners. Replies to open questions showed 
trialists suggest the need for clear guidance on how to 
conduct PPI in numerical aspects could help facilitate the 
behaviour, as well as having it as a requirement on ethics 
committees or standard operating procedures.
…REC [Research ethics committee] could remind when 
providing the final report to consider this. The Funder 
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often requires a report so they too could advise to do 
this. Being reminded by bodies that you have a regula-
tory or contractual obligation would help. May be jour-
nals could advise that this is done in their Instructions 
to Authors. The Research Design Service(RDS) also has 
PPI representatives on their teams and they could act in 
a capacity to remind people to do this. Internally in my 
unit, we could do with a guidance document about this. 
(Trial manager, involves)
Trial communication culture
Several comments from trialists talked to a broader issue with 
trial communication culture which highlighted the chal-
lenges with communicating clearly about numerical aspects 
with the entire trial team and ensuring everyone, including 
patient partners, fully understand them.
Numbers are presented to the PPI partners all the time 
in every trial… So they are involved, but it is by no means 
actually clear if they or indeed anybody else on the trial 
team actually understands the figures and the way they 
are presented. Are they actually any different from any-
body else on the trial team? Would improve transparency 
of decision making which I think would be an improve-
ment even if the actual decisions within the study do not 
qualitatively change. (Chief investigator, involves)
DISCUSSION
We have conducted a large UK- based survey to identify 
current practice, barriers and facilitators of involving public 
and patient partners in numerical aspects of trials . Because 
numerical aspects are central to the design, conduct, anal-
ysis and dissemination of trials, our study explicitly asks about 
involvement in such aspects rather than more broadly. Our 
sample represented a wide range of ages, professions and 
geographical regions in the UK. We used a theory- informed 
approach to design and analyse our findings to identify 
barriers and facilitators to involvement of public and patient 
partners in numerical aspects of trials. We found, in general, 
trialists believe involving public and patient partners in 
numerical aspects of trials is a good thing to do, but reported 
several barriers to doing it.
Around 60% of respondents to the survey reported to 
involve public and patient partners in the numerical aspects 
of trials; a similar percentage of women (62%) reported 
involving public and patient partners compared with men 
(66%). There was a lower percentage of early career trialists 
(up to 5 years of experience) doing this (49%) compared with 
more experienced trialists (72% and 63% for trialists with 
5–10 years of experience and over 10 years, respectively). This 
contrasts with the report that female and junior researchers 
are often tasked with doing PPI in health research,3 although 
it could be an artefact of respondents who are particularly 
interested in PPI. There is a higher proportion of trialists 
involving public and patient partners in surgical trials (92%4) 
or even in all trials, 10 or more years ago (75%5), than the 
proportion we found involving public and patient partners in 
numerical aspects. Most of our respondents involved public 
and patient partners in numerical aspects at the trial design 
(68%) or dissemination (63%) stages, with a significant 
percentage of respondents involving public and patient part-
ners in undertaking the trial (44%) and in its analysis (35%). 
Crocker et al’s survey of PPI in surgical trials4 and Raza et al’s 
audit of trials in the Integrated Research Application System13 
showed very similar patterns, although both observed a lower 
prevalence of involvement in the undertaking of a trial. Since 
involving patients and public partners in oversight commit-
tees is common practice2 but was not a stand- alone option 
in our survey, it is possible respondents included it as part of 
trial conduct.
There is scope to improve trialists’ knowledge, environ-
mental context and resources, and behavioural regulation 
regarding involving public and patient partners in numerical 
aspects of trials. Common reflections from the open questions 
revealed the need for training, more funding and resources, 
such as finding public and patient partners that are interested 
in being involved in numerical aspects of trials; developing 
guidelines about how and when public and patient partners 
can be involved in numerical aspects would be a natural next 
step. Trialists have also reported low recognition from public 
and patient partners, work peers and their managers. These 
findings are in line with other studies focused on general PPI 
in research3 14 and with wider PPI training needs requested 
by researchers working in clinical trials in the UK.15 However, 
this need was bigger in trialists who did not involve public and 
patient partners in numerical aspects of trials.
There was a clear difference in the perceived balance of 
benefits versus challenges of PPI in numerical aspects of trials 
between those who reported they did it (over 50% reported 
it as a positive balance) and those who did not (around 30% 
said the same). This is expected as professionals enacting a 
behaviour will tend to perceive more benefits than challenges 
compared with those who are not doing it. Respondents 
of the survey reported more accessible and implementable 
findings, the opportunity of questioning researchers, and 
more transparent partnerships between researchers and 
public and patient partners as benefits of involving public 
and patient partners in numerical aspects of trials. However, 
some respondents saw this as an extra time- consuming task 
with no evidence of improving the decision making in trials 
and/or having an impact of patient partners. It is possible 
these barriers appear more salient to those not involving 
patient and public partners in numerical aspects and the 
reasons for this can be varied, including their own workplace 
culture. This is reflected in numerous other studies about 
researchers’ motivations to involve patients and the public as 
partners in research and the ongoing debate about measur-
able impact.3 16
It is unclear who should be responsible for the involvement 
in numerical aspects of trials, given chief investigators, statis-
ticians and health economists traditionally have the role of 
analysing or sharing trial data and results, but trial managers 
are more often in charge of delivering PPI. This perception 
was echoed in the qualitative data where junior researchers, 
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trial managers and qualitative researchers suggested it was 
not their responsibility or it was difficult for them to involve 
public and patient partners in numerical aspects of trials. 
This was clearly an important factor in the respondents’ 
behaviour, since only three respondents (4%) considered 
involving public and patient partners in numerical aspects of 
trials as part of their role from trialists who were not currently 
performing the behaviour (vs 40% of those who did it).
There is uncertainty about public and patient partners’ 
motivation to get involved in numerical aspects of research. 
Around half of the respondents who involved public and 
patient partners in numerical aspects and 20% of trialists who 
do not perceived public and patient partners as being moti-
vated to get involved. The thematic analysis identified trialists 
perceived patient partners’ lack of interest or finding numbers 
‘boring’ as a barrier to involving them in numerical aspects 
of trials. Our survey included only four public and patient 
partner respondents and therefore cannot draw conclusions 
from their perspective, but there is scope for more research 
understanding public and patient partners’ expectations 
when it comes to involvement in numerical aspects of trials. 
However, it seems unlikely trialists could confidently speak on 
behalf of their public and patient partners in terms of moti-
vation to get involved in specific trial aspects. This is because 
a key challenge raised by several open question comments 
is the lack of definition of expectations about public and 
patient partners from the start. Defining expectations is not 
common practice, even though it is considered useful by all 
stakeholders.4 15
Tokenism and the idea that public and patient partners 
can only contribute to a limited number of tasks related to 
increasing readability may be a significant barrier to involving 
public and patient partners in numerical aspects of trials. A lot 
of respondents perceived numeracy and statistical knowledge 
as essential for public and patient partners to get involved in 
numerical aspects of randomised controlled trials and, in 
some cases, advanced knowledge about sample size calcula-
tions and analysis. This contrasts with the fact that public and 
patient partners often get involved in qualitative research and 
reinforces perceptions of disciplinary hierarchies,3 but could 
also be related to the fact that PPI and qualitative research 
have many common features and therefore seem a natural 
crossover.17 In fact, Boylan et al3 reported an assumption 
from UK researchers that the involvement of patients in qual-
itative interviewing and analysis is uncontroversial; some of 
our respondents have a clearly different view when it comes 
to public and patient partners’ involvement in quantitative 
analysis. From the public and patient partners’ perspective, a 
respondent pointed out that they often felt underestimated 
and another that tokenism is the main barrier to involving 
public and patient partners in numerical aspects. Wider liter-
ature on the topic shows there are appropriate methods to 
involve non- experts in discussions about statistical models 
and numbers,6 although this is a controversial topic.7 
Either way, communication, in particular about numerical 
aspects of trials, needs to improve to enable meaningful 
PPI in trials, and this has been known for almost a decade5 
and it is a key priority for future PPI research according to 
multiple stakeholders.18 A way forward could, for example, 
follow models to achieve better communication related to 
patient data, such as the Understanding Patient Data project 
(https:// unde rsta ndin gpat ientdata. org. uk/).
Limitations
Like with most complex behaviours, involving public and 
patient partners in numerical aspects of trials is in a spec-
trum. Respondents to our survey interpreted it in a variety of 
ways, ranging from presenting numbers in reports to public 
and patient partners at trial steering meetings to involving 
them in doing the statistical analysis. Despite the iterative 
development of a definition endorsed by multiple trial stake-
holders and its presentation at the beginning of the survey, 
it is likely that the barriers and facilitators presented here 
regard a range of behaviours in that spectrum. To develop 
the survey, our PPI was limited to piloting. Since the survey 
aimed to understand practices, barriers and facilitators for 
professionals, we considered this to be sufficient within the 
context of a master’s student’s project, but patient and public 
partners’ perspective could have enriched the study questions 
and survey design and potentially increased the number of 
patient and public partners responding. We did not include 
a stand- alone option of PPI in the numerical aspects of data 
and trial steering committees; however, we do not consider 
this to be essential information to our purpose (a broad over-
view of PPI in numerical aspects of trials), and nevertheless 
respondents added this information in open questions. Qual-
itative analysis was based on open questions in a survey which 
are limited in their scope when compared with conducting 
interviews and may lead to misinterpretation of answers.19 We 
tried to minimise this by double assessing a subsample of qual-
itative data. Our sample was diverse and came from multiple 
locations and professions across the country. Respondents 
who answered demographic questions but did not proceed 
to answering questions specifically about PPI in numerical 
aspects of trials were mostly similar to those who did; however, 
we are likely to have respondents who have stronger views of 
PPI and PPI in numerical aspects of trial since they opted to 
answer our survey.
CONCLUSION
We found a generally positive attitude towards involving 
public and patient partners in numerical aspects of trials, 
with 60% of the respondents reporting attempting to do 
so in a variety of ways. However, there is a need to under-
stand public and patient partners’ expectations when 
getting involved in a trial and whether they would have 
an interest in being involved in numerical aspects. To 
achieve this, public and patient partners first need to be 
aware of the different stages of trials and the opportuni-
ties to get involved. Numerical aspects are a key element 
in trials and therefore should at least be part of an initial 
discussion. Our survey has also highlighted that commu-
nication of numerical and methodological aspects of trials 
can be challenging, not just for public and patient part-
ners but for the whole trial team. Improving it should be 
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a matter of providing training on either communication 
skills, technical aspects or both, and it should be available 
for the whole team, including but not limited to public 
and patient partners. A training set codesigned by rele-
vant stakeholders and available to all clinical trials units 
in the UK, including successful case studies of involving 
public and patient partners in numerical aspects of trials, 
is an essential step forward, as well as guidance on what 
are the most relevant numerical aspects of trials to involve 
public and patient partners in and how to do that in a 
meaningful way.
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Demographic questions  
Questions Response options 
What is your age? 18-24 years old 
25-34 years old 
35-44 years old 
45-54 years old 
55-64 years old 
65-74 years old 
75 years or older 
Gender: What is your gender?  Female 
Male 
Other 
Rather not say 
Geographic: Where is your workplace is based? England 
 North East England 
 North West England  
 Yorkshire and the Humber 
 West Midlands  
 East Midlands  
 South West England  
 South East England 
 London  
 East England 
Northern Ireland  
Scotland  
Wales  
Job: What is your main role in the trial? Trial Manager  
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Don’t work in a trial   
 
Other 
Job: How long have you worked in clinical trials?  Less than 5 years 
Between 5-10 years  
More than 10 years 
Job: Which aspects of the trials process are you directly involved 
in? 
Trial design  
 
Undertaking the trial (e.g. identifying or recruiting participants, collecting data) 
 
Analysis and/or interpretation of results 
 
Dissemination of findings 
 
None of the above 
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Current behavior / beliefs 
Questions Response options 
 How often are you involved in the numerical aspects of a trial, according to the definition above?  1: never 
2: rarely 
3: regularly 
2: every day 
0: other 




3: don’t know 
Can you provide the reasons for why you do, or do not, involve patient or public partners in the 
numerical aspects of trials? 
Open question 
What stage of a trial do you involve public or patient partners in the numerical aspects of a trial?  Research design 
Undertaking the research (e.g. Identifying or recruiting 
participants, collecting data) 
Analysis and/or interpretation of results 
Dissemination of findings 
None of the above 
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Other (please specify) 
When you involve patient or public partners in the numerical aspects of a trial, where on the scale 
do you picture yourself? 
0-100 (informing – co-producing) 
When involving patient or public partners in numerical aspects, do you think the patient or public 
partners need to have particular experience or skills? 
1: yes 
2: no 
If you answered "Yes" to the last questions, what kind of experience or skills are you looking for? Open question 
 
Theoretical domains framework questions 
Questions Response 
options 
On a scale of 1 to 7, how familiar are you with involving patient or public partners in numerical aspects of trials ? Scale 1-7, 1 being not at 
all familiar and 7 being very familiar 
1-7 
What do you know about how to involve patient or public partners in numerical aspects of trials? Please provide examples of when this 
has worked well. 
Open question 
On a scale of 1 to 7, grade your own ability to involve patient or public partners in numerical aspects of trials? Scale 1 – 7: 1 being 
unable and 7 being very able 
1-7 
Is involving patient or public partners in numerical aspects of trials an expected role within your job? E.g. an explicit goal or objective 
within your job specification 
1: yes  
2: no 
0: other 
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On a scale of 1 to 7, do you feel confident in your ability to involve patient or public partners in numerical aspects of trials? Scale 1- 7, 1 
being unable and 7 being very able  
1-7 
Do you think that involving patient or public partners in numerical aspects of trials is hard to deliver? 1: yes 
2: no 
0: other 
If you answered "Yes", what it is that makes it hard and what could make it easier? Open question 
On a scale of 1 to 7, how much do you agree with this sentence? Involving patient or public partners in numerical aspects of trials is a 
good thing. Scale 1 – 7, 1 being do not agree and 7 being completely agree 
 
Do you think involving patient or partners in numerical aspects of a trial can have a positive impact on the following groups?  
• On the researcher 1: Yes – 
positive impact 
2: No – no 
impact 
3: No – 
negative 
impact 
• On the quality of trial 1: Yes – 
positive impact 
2: No – no 
impact 
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3: No – 
negative 
impact 
• On the patient partner 1: Yes – 
positive impact 
2: No – no 
impact 
3: No – 
negative 
impact 
If you answer "No" to one of the questions, please specify why you think public or patient partners in numerical aspects of trials have no 
impact or a negative impact 
Open question 
What positive impacts can patient or public partners have on the numerical aspects of trials? Open question 
Do you think that there is a good balance between the challenges of involving patient or public partners in numerical aspects of trials 
(e.g. the difficulty of operationalization or implementation) and the potential benefits of patient or public partners involvement? 
1: yes 
2: no 
When you involve patient or public partners in numerical aspects of trials,  do you get a reward or recognition from the 
following groups?  
 
• Patient and public partners 1: yes 
2: no 
• My work peers 1: yes 
2: no 
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• My line manager 1: yes 
2: no 
Please tell us who else rewards or recognizes you when you involve public and patient partners in numerical aspects of trials Open question 
Will you involve patient or public partners in numerical aspects in your next project? 1: yes definitely 
2: yes probably 
3: no definitely 
4: no probably 
5: I don’t know 
On a scale of 1 to 7, how much do you agree with this sentence?  Working on something else on my agenda is a higher priority or more 
urgent than involving patient or public partners in the numerical aspects of trials. 
1-7 
On a scale of 1 to 7, how much do you agree with this sentence? Involving patient or public partners in numerical aspects of trials is 
something I do automatically. 
1-7 
Do you have the resources you need to involve patient or public partners in numerical aspects of trials? 1: yes 
2: no 
Do you agree with these sentences?   
• University/Employer provides training to involve patient or public partners in numerical aspects of trials. 1: yes 
2: no 
• Involving patient or public partners in numerical aspects of trials is compatible with daily practice 1: yes 
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• Patient or public partners are motivated to get involved in numerical aspects of trials 1: yes 
2: no 
What in your work environment could help to involve patient or public partners in numerical aspects of trial? Open question 
What in your work environment could be a barrier to involve patient or public partners in numerical aspects of trial? Open question 
On a scale of 1 to 7, how much do you agree with this sentence?  Most people who are important (E.g. co-workers, peers) think that I 
should involve patient or public partners in numerical aspects of trials  
1-7 
From the list below, who encourages you to involve patient or public partners in numerical aspects of trials?  Tick all the 
relevant boxes no maximum  
 
• Myself  
• Co-workers  
• Manager  
• Scientific literature  
• Social media  
• My personal environment  
• Public  
• Institution  
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• Regulation  
• Mass media  
• No encouragement  
• Other  
On the list below, who is a barrier for you involve patient or public partners in numerical aspect of trials?   
• Myself  
• Co-workers  
• Manager  
• Scientific literature  
• Social media  
• My personal environment  
• Public  
• Institution  
• Regulation  
• Mass media  
• No encouragement  
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• Other  















Do you have a clear plan on which numerical aspects of trials you should involve the patient or partners with? 1: yes 
2: no 
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Do you have a clear plan on how you will involve the patient or public partners in the numerical aspects of trials?  1: yes 
2: no 
Do you have a clear plan on how often you will involve the patient or public partners in numerical aspects of trials? 1: yes 
2: no 
Is there anything that would remind you to involve patients or public partners in numerical aspects of trials? Open question 
On a scale of 1 to 7, how much do you agree with this sentence?  I involve patient or public partners in numerical aspects of trials without 
having to consciously thinking about it.  Scale 1-7, 1 being not at all and 7 being definitely 
1-7 
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Supplementary Table 1 – Demographic characteristics by respondent status (respondents were 
defined as participants that replied to demographic characteristics and all theoretical domains 





Age   
18-24 years old 2 (1.1) 3 (3.0) 
25-34 years old 62 (33.2) 27 (27.3) 
35-44 years old 50 (26.7) 35 (35.4) 
45-54 years old 41 (21.9) 20 (20.2) 
55-64 years old 22 (11.8) 9 (9.1) 
65+ years old 7 (3.7) 4 (4.0) 
Rather not say 3 (1.6) 1 (1.0) 
Gender   
Female 130 (69.5) 82 (82.8) 
Male 50 (26.7) 17 (17.2) 
Other 2 (1.1)  
Prefer not to say 5 (2.7)  
Work location   
England 17 (9.1) 10 (10.1) 
North East England 7 (3.7) 3 (3.0) 
North West England 14 (7.5) 7 (7.1) 
Yorkshire and the Humber 13 (7.0) 11 (11.1) 
West Midlands 12 (6.4) 1 (1.0) 
East Midlands 7 (3.7) 6 (6.1) 
South West England 11 (5.9) 6 (6.1) 
South East England 19 (10.2) 10 (10.1) 
London 33 (17.6) 18 (18.2) 
East England 4 (2.1) 3 (3.0) 
Northern Ireland 6 (3.2) 5 (5.1) 
Scotland 30 (16.0) 16 (16.2) 
Wales 14 (7.5) 3 (3.0) 
Which aspects of the trial process are you directly 
involved in? 
  
Trial design 88 (47.1) 51 (51.5) 
Undertaking the trial 85 (45.5) 50 (50.5) 
Dissemination 89 (47.6) 39 (39.4) 
Analysis 59 (31.6) 24 (24.2) 
Overseeing committee 5 (2.7) 1 (1.0) 
All stages 75 (40.1) 25 (25.3) 
None  1 (1.0) 
Main role in trial   
Trial manager 125 (66.8) 69 (69.7) 
Chief investigator 3 (1.6)  
Statistician 29 (15.5) 8 (8.1) 
Health economist 3 (1.6) 3 (3.0) 
Qualitative researcher 8 (4.3)  
Patient Partner 8 (4.3) 3 (3.0) 
Co-investigator 16 (8.6) 10 (10.1) 
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Researcher 7 (3.7) 6 (6.1) 
Systematic reviewer 1 (0.5)  
Programmer  1 (1.0) 
PPI lead 3 (1.6) 4 (4.0) 
Don't work in a trial  2 (2.0) 
Missing 63 (33.2) 30 (30.3) 
How long have you been working in trials?   
Less than 5 years 57 (30.5) 35 (35.4) 
Between 5-10 years 61 (32.6) 28 (28.3) 
More than 10 years 69 (36.9) 36 (36.4) 
When do you involve patient or public partners in 
numerical aspects of trials? 
  
Never 7 (3.7) 7 (7.1) 
Rarely 23 (12.3) 18 (18.2) 
Regularly 109 (58.3) 57 (57.6) 
Every day 48 (25.7) 11 (11.1) 
Missing  6 (6.1) 
Do you involve patient or public partners in the 
numerical aspects of trials? 
  
Yes 116 (62.0) 18 (18.2) 
No 48 (25.7) 6 (6.1) 
Don't know 23 (12.3) 3 (3.0) 
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Supplementary Table 2 – Responses to the Theoretical Domains Framework questions by whether 
respondent said they involved patient and public partners (PPP) in numerical aspects of trials – 




Respondents do not 
involve PPP or are not 
sure (N=71) 
TDF domain: Knowledge   
How familiar are you with involving PPP in 
numerical aspects of trials? 
4 (3.0-5.0),116 2 (1.0-3.0),71 
TDF domain: Skills   
Grade your own ability to involve PPP in 
numerical aspects of trials 
4 (3.0-5.0),116 2 (1.0-4.0),71 
TDF domain: Social / professional role   
Is involving PPP in numerical aspects of trials an 
expected role within your job? 
46 (39.7) 3 (4.2) 
TDF domain: Beliefs about capability   
Do you feel confident in your ability to involve 
PPP in numerical aspects of trials? 
4 (3.0-5.0),111 3 (2.0-4.0),62 
Do you think that involving PPP in numerical 
aspects of trials is hard to deliver? 
52 (44.8) 34 (47.9) 
TDF domain: Optimism   
Involving PPP in numerical aspects of trials is a 
good thing 
6 (5.0-7.0),108 5 (4.0-6.0),61 
Do you think involving patient or partners in 
numerical aspects of a trial can have a positive 
impact on the researcher? 
  
Yes 96 (82.8) 43 (60.6) 
No impact 5 (4.3) 11 (15.5) 
Negative impact 1 (0.9) 2 (2.8) 
Missing 14 (12.1) 15 (21.1) 
on the quality of the trial?   
Yes 93 (80.2) 46 (64.8) 
No impact 8 (6.9) 9 (12.7) 
Negative impact 1 (0.9) 1 (1.4) 
Missing 14 (12.1) 15 (21.1) 
on the patient partner?   
Yes 95 (81.9) 50 (70.4) 
No impact 6 (5.2) 4 (5.6) 
Negative impact 1 (0.9) 2 (2.8) 
Missing 14 (12.1) 15 (21.1) 
TDF domain: beliefs about consequences   
There is a good balance between the challenges 
of involving PPP in numerical aspects of trials 
and the potential benefits 
68 (58.6) 22 (31.0) 
TDF domain: Reinforcement   
You get recognition from PPP, when you involve 
them in numerical aspects of trials 
35 (30.2) 12 (16.9) 
You get recognition from work peers 21 (18.1) 5 (7.0) 
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You get recognition from your manager 23 (19.8) 6 (8.5) 
TDF domain: Intention   
Will you involve PPP in numerical aspects of 
your next project? 
  
Yes definitely 41 (35.3) 4 (5.6) 
Yes probably 42 (36.2) 16 (22.5) 
No definitely 0 1 (1.4) 
No probably 4 (3.4) 9 (12.7) 
I don’t know 12 (10.3) 24 (33.8) 
Missing 17 (14.7) 17 (23.9) 
TDF domain: Goals   
Working on something else on my agenda is a 
higher priority than involving PPP in the 
numerical aspects of trials 
4 (3.0-5.0),99 5 (4.0-6.0),54 
TDF domain: Memory, attention, decision 
process 
  
Involving PPP in numerical aspects of trials is 
something I do automatically 
4 (3.0-6.0),93 2 (1.0-2.5),52 
TDF domain: Environmental context and 
resources 
  
Have the resources needed to involve PPP in 
numerical aspects of trials 
55 (47.4) 16 (22.5) 
Employer provides support to involve PPP in 
numerical aspects of trials 
47 (40.5) 13 (18.3) 
Employer provides training to involve PPP in 
numerical aspects of trials 
31 (26.7) 7 (9.9) 
Involving PPP in numerical aspects of trials is 
compatible with daily practice 
63 (54.3) 17 (23.9) 
PPP are motivated to get involved in numerical 
aspects of trials 
59 (50.9) 14 (19.7) 
TDF domain: Social influences   
Most people who are important think I should 
involve PPP in numerical aspects of trials 
5 (4.0-6.0),94 3 (1.0-4.0),50 
Who encourages you to involve PPP in 
numerical aspects? 
  
Myself 63 (54.3) 15 (21.1) 
Co-workers 45 (38.8) 11 (15.5) 
Manager 44 (37.9) 10 (14.1) 
Social media 14 (12.1) 6 (8.5) 
My personal environment 18 (15.5) 1 (1.4) 
Scientific literature 31 (26.7) 15 (21.1) 
Public 24 (20.7) 9 (12.7) 
Institution 38 (32.8) 10 (14.1) 
Regulation 22 (19.0) 15 (21.1) 
Mass media 3 (2.6) 3 (4.2) 
No encouragement 7 (6.0) 14 (19.7) 
Who is a barrier for you to involve PPP in 
numerical aspects? 
  
Myself 6 (5.2) 7 (9.9) 
Co-workers 4 (3.4) 7 (9.9) 
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Manager 6 (5.2) 10 (14.1) 
Scientific literature 2 (1.7) 3 (4.2) 
Social media 2 (1.7)  
My personal environment 11 (9.5) 6 (8.5) 
Public 5 (4.3) 7 (9.9) 
Institution 13 (11.2) 13 (18.3) 
Regulation 10 (8.6) 5 (7.0) 
Mass media 5 (4.3) 3 (4.2) 
No barrier 47 (40.5) 13 (18.3) 
TDF domain: Emotions   
Emotions related to involving PPP in numerical 
aspects 
  
Optimism 65 (56.0) 29 (40.8) 
Ease 18 (15.5) 5 (7.0) 
Calm 14 (12.1) 3 (4.2) 
Relaxation 3 (2.6) 3 (4.2) 
Appreciation 71 (61.2) 32 (45.1) 
Nervousness 37 (31.9) 18 (25.4) 
Pessimism 7 (6.0) 12 (16.9) 
Depression  2 (2.8) 
Agitation 9 (7.8) 11 (15.5) 
Happiness 27 (23.3) 8 (11.3) 
Sadness 2 (1.7) 2 (2.8) 
Anxiety 25 (21.6) 17 (23.9) 
TDF domain: Behavioural regulation   
Do you have a clear plan on…   
Which numerical aspects of trials you should 
involve PPP with? 
33 (28.4) 5 (7.0) 
How you will involve PPP in numerical aspects 
of trials? 
36 (31.0) 6 (8.5) 
How often will you involve PPP in numerical 
aspects of trials? 
37 (31.9) 4 (5.6) 
TDF domain: Nature of behaviour   
Involve PPP in numerical aspects of trials 
without consciously thinking about it 
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Reporting checklist for cross sectional study. 
Based on the STROBE cross sectional guidelines. 
Instructions to authors 
Complete this checklist by entering the page numbers from your manuscript where readers will find 
each of the items listed below. 
Your article may not currently address all the items on the checklist. Please modify your text to 
include the missing information. If you are certain that an item does not apply, please write "n/a" and 
provide a short explanation. 
Upload your completed checklist as an extra file when you submit to a journal. 
In your methods section, say that you used the STROBE cross sectionalreporting guidelines, and cite 
them as: 
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening 
the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for 
reporting observational studies. 





   
Title #1a Indicate the study’s design with a commonly used term in the 
title or the abstract 
1 
Abstract #1b Provide in the abstract an informative and balanced summary 
of what was done and what was found 
1 
Introduction    
Background / 
rationale 
#2 Explain the scientific background and rationale for the 
investigation being reported 
3 
Objectives #3 State specific objectives, including any prespecified 
hypotheses 
3 
Methods    
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Study design #4 Present key elements of study design early in the paper 3 
Setting #5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data collection 
4 
Eligibility criteria #6a Give the eligibility criteria, and the sources and methods of 
selection of participants. 
4 
 #7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
3-4 
Data sources / 
measurement 
#8 For each variable of interest give sources of data and details of 
methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one 
group. Give information separately for for exposed and 
unexposed groups if applicable. 
3-4 
Bias #9 Describe any efforts to address potential sources of bias NA 
Study size #10 Explain how the study size was arrived at 3-4 
Quantitative 
variables 
#11 Explain how quantitative variables were handled in the 















#12c Explain how missing data were addressed 4-5 
Statistical 
methods 





#12e Describe any sensitivity analyses 4-5 
Results    
Participants #13a Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, confirmed 
5, Fig 1 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046977:e046977. 11 2021;BMJ Open, et al. Goulao B
eligible, included in the study, completing follow-up, and 
analysed. Give information separately for for exposed and 
unexposed groups if applicable. 
Participants #13b Give reasons for non-participation at each stage NA 
Participants #13c Consider use of a flow diagram 5, Fig 1 
Descriptive data #14a Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders. Give information separately for exposed and 
unexposed groups if applicable. 
p5, 
Table 1 
Descriptive data #14b Indicate number of participants with missing data for each 




Outcome data #15 Report numbers of outcome events or summary measures. 
Give information separately for exposed and unexposed 
groups if applicable. 
Table 2 
Main results #16a Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and 
why they were included 
NA 
Main results #16b Report category boundaries when continuous variables were 
categorized 
NA 
Main results #16c If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period 
NA 
Other analyses #17 Report other analyses done—e.g., analyses of subgroups and 
interactions, and sensitivity analyses 
NA 
Discussion    
Key results #18 Summarise key results with reference to study objectives 9-11 
Limitations #19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias. 
11 
Interpretation #20 Give a cautious overall interpretation considering objectives, 
limitations, multiplicity of analyses, results from similar studies, 
9-11 
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and other relevant evidence. 





   
Funding #22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on which 
the present article is based 
12 
Notes: 
• 14a: p5, Table 1 
• 14b: p5, Tables 1,2 The STROBE checklist is distributed under the terms of the Creative 
Commons Attribution License CC-BY. This checklist was completed on 14. November 2020 
using https://www.goodreports.org/, a tool made by the EQUATOR Network in collaboration with 
Penelope.ai 
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